The 17 brand-name drugs that saw prices more than double in 6 years

Seventeen top-selling brand-name drugs saw their prices more than double over a six-year period, according to a new study published in The Journal of the American Medical Association.

For the study, published May 31, researchers from the Scripps Research Translational Institute analyzed six years of pharmacy claims data from a Blue Cross Blue Shield Axis database. The researchers focused on prescription data about 49 top-selling brand-name drugs submitted from January 2012 and December 2017. Only drugs that exceeded $500 million in U.S. sales or $1 billion in global sales were examined.

The drugs that saw the biggest price jumps, by percent change, were:

1. Viagra (190 percent)
2. Cialis (187 percent)
3. Forteo (177 percent)
4. Lexapro (150 percent)
5. Zetia (149 percent)
6. Lyrica (137 percent)
7. Lipitor (137 percent)
8. Renvela (136 percent)
9. Enbrel (133 percent)
10. Premarin (129 percent)
11. Humira (124 percent)
12. Chantix (124 percent)
13. Onfi (118 percent)
14. Novolog (118 percent)
15. Humulin (117 percent)
16. Humalog (117 percent)
17. Simponi (107 percent)

More articles on pharmacy:
Viewpoint: The $2.1M drug price record won't last long
J&J to cut 61 jobs in New Jersey
Mallinckrodt to spin off generics unit

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months